In the early days of the COVID-19 pandemic, when researchers scrambled to find drugs that could treat this new type of disease, Gilead Sciences company Veklury relied on promising early data and was quickly put into clinical use. A few days ago, Gilead said that as the drug has now been fully approved by the U.S. Food and Drug Administration (FDA), Veklury’s sales have achieved substantial growth, and it is expected to achieve large-scale growth in 2021.
Veklury was previously known as remdesivir (remdesivir), and the drug will bring Gilead in revenue of $2.8 billion in 2020. Most of the drug's revenue came from the fourth quarter, mainly due to the surge in hospitalized patients and COVID-19 treatment cases at that time, and the use of Veklury also peaked. In terms of specific data, after the drug brought in revenue of US$873 million in the third quarter of 2020, due to the failure of effective control of the epidemic in the fourth quarter, the sales revenue of the drug also hit a record high, reaching a staggering 19.3 One hundred million U.S. dollars.
After preliminary research, Veklury obtained an emergency use authorization from the FDA in May and received full approval in October. Although experts debated the data and effectiveness of various clinical trials of Veklury, Veklury eventually became the standard treatment for hospitalized patients with new coronary pneumonia. Now, even if the new crown vaccine has been successfully developed and marketed, the catastrophic situation caused by the new crown pneumonia pandemic means that many patients with new crown pneumonia still need to be hospitalized around the world. However, in November, the World Health Organization (WHO) issued a dynamic update guide for drugs for the treatment of new coronary pneumonia. The focus of the update is remdesivir. Regardless of the severity of the disease, the guidelines do not recommend the use of remdesivir in hospitalized patients with new coronary pneumonia. The recommended intensity level is Weak or conditional recommendation. Regarding this, Gilead is still optimistic that Veklury’s sales in 2021 are expected to reach US$2 billion to US$3 billion.
Although the launch of the vaccine may gradually reduce the number of people infected with new coronary pneumonia, the effectiveness and safety of the vaccine have also attracted more and more attention and doubts from the outside world. Pfizer is still optimistic that the sales revenue of its new crown vaccine will reach 15 billion U.S. dollars after the injection of vaccines caused dozens of deaths worldwide. A few days ago, a nursing home in Spain soon after being vaccinated with Pfizer, 90 people in the hospital were infected with the new crown virus, of which 7 people have died and 4 people are in a state of intensive treatment.
The CEO of Moderna, another vaccine manufacturer, said that the company is expected to be among the top manufacturers of new crown vaccines by the end of the year. Eli Lilly also predicts that 2021 sales of antibodies against the new coronavirus will reach between US$1 billion and US$2 billion. In addition to Veklury, due to the impact of generic drugs on Truvada and Atripla, Gilead’s sales in 2020 fell by 3% to US$21.5 billion. In the fourth quarter, due to the impact of generic drugs and price pressures, the company's key business growth point, sales of the AIDS product line fell by 7% to US$4.26 billion.
However, Gilead’s chief financial officer Andrew Dickinson said on an analyst conference call last Thursday that Gilead expects the company to continue to grow in the “short-term”, “medium” and “long-term”. The company expects its "core business" to achieve high-level single-digit growth, excluding Veklury and drugs whose patent protection has recently been lost. Gilead believes that AIDS drug Biktarvy, tumor drug Trodelvy and chronic hepatitis B treatment Vemlidy and cell Therapies are expected to drive continued growth in performance.
Dickinson said, “Although there are still uncertainties about the new crown pneumonia pandemic, we have made certain assumptions about the dynamic recovery of the potential market from the second quarter of 2021.” Gilead expects that the company will remove Veklury sales in 2021. The amount will hopefully reach between 21.7 billion and 22.1 billion US dollars. If Veklury is included, sales are expected to reach between 23.7 billion and 25.1 billion US dollars.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Novel self-healing material for potential application in space coatings
Novel antiviral coating to reduce the spread of COVID-19
A major investment project of 6 billion high-end new materials settled
Top 30 best-selling oncology drugs in the world in 2020
The tight supply of ethylene glycol is difficult to change
Thermoplastic polyurethane (TPU) price increase!